A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate

[11] Danckaerts M(2011)Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry. 50 395-463

[12] Sonuga-Barke EJ(2007)Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther. 29 450-1092

[13] Banaschewski T(2013)A head-to-head, randomized, double-blind, phase 3b study comparing the efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder CNS Drugs. 27 1081-119

[14] Buitelaar J(2006)Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder J Pediatr. 149 112-1685

[15] Döpfner M(2014)Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine Curr Med Res Opin. 30 1673-257

[16] Hollis C(2011)Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations Patient. 4 247-132

[17] Doshi JA(2003)The Health Utilities Index (HUI): concepts, measurement properties and applications Health Qual Life Outcomes. 1 54-975

[18] Hodgkins P(2005)Comparative effectiveness: asking the right questions, choosing the right method Health Aff (Millwood) 24 128-1289

[19] Kahle J(2013)Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis J Med Econ. 16 962-undefined

[20] Sikirica V(2013)Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications J Med Econ. 16 1275-undefined

[11] Danckaerts M(2011)Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry. 50 395-463

[12] Sonuga-Barke EJ(2007)Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther. 29 450-1092

[13] Banaschewski T(2013)A head-to-head, randomized, double-blind, phase 3b study comparing the efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder CNS Drugs. 27 1081-119

[14] Buitelaar J(2006)Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder J Pediatr. 149 112-1685

[15] Döpfner M(2014)Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine Curr Med Res Opin. 30 1673-257

[16] Hollis C(2011)Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations Patient. 4 247-132

[17] Doshi JA(2003)The Health Utilities Index (HUI): concepts, measurement properties and applications Health Qual Life Outcomes. 1 54-975

[18] Hodgkins P(2005)Comparative effectiveness: asking the right questions, choosing the right method Health Aff (Millwood) 24 128-1289

[19] Kahle J(2013)Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis J Med Econ. 16 962-undefined

[20] Sikirica V(2013)Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications J Med Econ. 16 1275-undefined